Moore Capital Management’s Minerva Neurosciences NERV Stock Holding History

Moore Capital Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3,125	Closed	-$80K	–	575
2020 Q3	$80K	Hold	3,125	–	–	﹤0.01%	365
2020 Q2	$90K	Sell	3,125 -6,250	-67%	-$367K	﹤0.01%	248
2020 Q1	$452K	Hold	9,375	–	–	0.02%	141
2019 Q4	$533K	Sell	9,375 -2,516	-21%	-$111K	0.02%	216
2019 Q3	$737K	Hold	11,891	–	–	0.03%	245
2019 Q2	$536K	Sell	11,891 -6,859	-37%	-$343K	0.01%	266
2019 Q1	$1.18M	Hold	18,750	–	–	0.04%	227
2018 Q4	$1.01M	Sell	18,750 -4,075	-18%	-$298K	0.04%	173
2018 Q3	$2.29M	Sell	22,825 -2,175	-9%	-$163K	0.05%	189
2018 Q2	$1.65M	Buy	+25,000	New	+$1.52M	0.04%	191
2017 Q3	–	Sell	-3,125	Closed	-$221K	–	251
2017 Q2	$221K	Buy	+3,125	New	+$202K	0.01%	183

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Moore Capital Management's NERV Position: Q4 2020 in Review

Moore Capital Management sold out of Minerva Neurosciences (NERV) in Q4 2020, closing a stake of 3,125 shares — an estimated $80K sold.

Moore Capital Management first reported a position in NERV in Q2 2017 and held it in 11 quarters. The position peaked at $2.29M in Q3 2018. 76 funds tracked by Wall St. Rank hold NERV as of Q4 2020.

Moore Capital Management reported no remaining Minerva Neurosciences position as of Q4 2020 after selling out during the quarter.
Moore Capital Management sold 3,125 Minerva Neurosciences shares in Q4 2020, an estimated $80K.
Moore Capital Management first reported a position in Minerva Neurosciences in Q2 2017 and held it in 11 quarters.
Moore Capital Management's Minerva Neurosciences position peaked at $2.29M in Q3 2018.
76 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2020.

Based on Moore Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.